Price
No data yet.
Social Signal Score
Analyst Ratings
31 analystsRevenue
$8.50M-96.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David R. Lukes
- Sector
- Real Estate
- Industry
- REIT - Retail
- Employees
- 155
- Beta
- 1.00
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -13.66
Financials
Revenue
$8.50M-96.3%Net Income
$-5.39M-116.0%EBITDA
$-2.85M-101.8%Free Cash Flow
$-6.71M-105.9%EPS (diluted)
$-0.10-115.6%Shares Outstanding (diluted)
52.48M+14.7%Operating Expenses
$8.99MCash & Debt
$200.21MReturn of Capital
$52.70MRevenue by Segment (annual)
$5.00MDividend per Share
$3.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $123.17M | $177.86M | $3.39 |
| 2024 | $277.47M | $531.82M | $9.81 |
| 2023 | $452.62M | $265.70M | $4.85 |
| 2022 | $479.22M | $168.72M | $2.96 |
| 2021 | $532.86M | $124.94M | $2.04 |
| 2020 | $460.33M | $35.72M | $0.74 |
| 2019 | $507.10M | $100.70M | $2.20 |
| 2018 | $654.86M | $-109.30M | $-2.37 |
| 2017 | $879.45M | $-241.69M | $-5.26 |
| 2016 | $969.51M | $60.01M | $1.31 |
| 2015 | $995.10M | $-72.17M | $-1.60 |
| 2014 | $953.77M | $117.28M | $2.00 |
| 2013 | $888.79M | $-10.18M | $-0.25 |
| 2012 | $800.38M | $-25.82M | $-0.72 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.98
- Implied price
- $89.69
- Return from $0.66
- 167.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $44.59 — today's price is already 98.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 123.7% | 133.9% | 142.6% | 150.2% | 156.9% |
| 3.0% | 135.1% | 145.8% | 154.9% | 162.9% | 170.0% |
| 8.0% | 146.5% | 157.8% | 167.3% | 175.7% | 183.2% |
| 13.0% | 157.9% | 169.7% | 179.7% | 188.5% | 196.3% |
| 18.0% | 169.3% | 181.6% | 192.1% | 201.2% | 209.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-70.91%Social Signal Score
Mentions (21)
- Newsglobenewswire.com·13d ago·Negative
Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), a biopharmaceutical company that has developed conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced new clinical data from its Phase 1/1b clinical trial of…
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
… Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced updated interim monotherapy results from its ongoing Phase 1/2…
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
…rapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced preclinical findings from two studies presented at the 41st Annual Meeting of the Society for Immunotherapy …
View source ↗ - Newsbusinesswire.com·16d ago·Negative
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from …
View source ↗ - Newsnewsfilecorp.com·16d ago·Negative
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced to…
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for linoserpaturev in recurrent glioblastoma PrTK05 data show systemic cytotoxic T-cell activation following intraprostatic administration of aglatima…
View source ↗ - Newsglobenewswire.com·16d ago·Negative
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced preclinical findings from four poster…
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
…inations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8-fold with atebimetinib plus anti-PD-1 and chemotherapy versus anti-PD-1 plus chemotherapy alone in a RAS-mut…
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…f agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
View source ↗ - Newsglobenewswire.com·23d ago·Negative
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it has been selected f…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: E…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from…
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting tak…
View source ↗ - Newsaccessnewswire.com·39d ago·Neutral
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecifi…
View source ↗ - Newsglobenewswire.com·47d ago·Negative
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their r…
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at …
View source ↗ - Newsbusinesswire.com·51d ago·Negative
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant adva…
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Canc…
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer pa…
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Candel Therapeutics to Present at the SITC 2026 Annual Meeting NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite i…
View source ↗
Earnings
Wed, Feb 17(in 3 months)
Consensus estimate $-0.11 per share
Typical surprise +116.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$-0.06 vs $-0.10beat
- Mon, Aug 3$-0.03 vs $-0.11beat
- Thu, May 7$0.02 vs $-0.11beat
- Thu, Feb 26$2.55 vs $-0.24beat
- Wed, Nov 5$-0.13 vs $-0.26beat
- Tue, Aug 5$0.88 vs $-0.16beat
Estimates and results for SITC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SITC officers and directors.
- Bought
- —
- Sold
- $60.2m
0 trades
23 trades
- Kitlowski Aaronsold
- Cattonar John Msold
- Sweeney Dawn M.sold
- Sweeney Dawn M.sold
- Lukes David Rsold
- Lukes David Rsold
- Fennerty Conorsold
- Otto Alexandersold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (328d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 11, 2018 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
